{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:51:04Z","timestamp":1790855464489,"version":"4.1.0"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T00:00:00Z","timestamp":1639008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI142785"],"award-info":[{"award-number":["U19AI142785"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"DOI":"10.1371\/journal.ppat.1010078","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T13:31:49Z","timestamp":1639056709000},"page":"e1010078","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":119,"title":["Current state of Ebola virus vaccines: A snapshot"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3389-0137","authenticated-orcid":true,"given":"Courtney","family":"Woolsey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-1877","authenticated-orcid":true,"given":"Thomas W.","family":"Geisbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,12,9]]},"reference":[{"issue":"19","key":"ppat.1010078.ref001","first-page":"1832","article-title":"Geisbert TW. Ebola","volume":"382","author":"H Feldmann","year":"2020","journal-title":"N Engl J Med"},{"key":"ppat.1010078.ref002","unstructured":"Centers for Disease Control and Prevention. Ebola (Ebola virus disease): History of Ebola Virus Disease (EVD) Outbreaks [updated June 2021] [cited 2021 Oct 4]. Available from: http:\/\/www.cdc.gov\/vhf\/ebola\/history\/chronology.html."},{"issue":"10068","key":"ppat.1010078.ref003","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"AM Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"ppat.1010078.ref004","unstructured":"World Health Organization. Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response. 10 April 2019 meeting report. [cited 2021 Oct 4]. Available from: https:\/\/www.who.int\/csr\/resources\/publications\/ebola\/ebola-ring-vaccination-results-12-april-2019.pdf."},{"key":"ppat.1010078.ref005","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3389\/fimmu.2018.01025","article-title":"Herd Immunity to Ebolaviruses Is Not a Realistic Target for Current Vaccination Strategies","volume":"9","author":"SG Masterson","year":"2018","journal-title":"Front Immunol"},{"issue":"11","key":"ppat.1010078.ref006","doi-asserted-by":"crossref","first-page":"e0007814","DOI":"10.1371\/journal.pntd.0007814","article-title":"Vaccination strategies to control Ebola epidemics in the context of variable household inaccessibility levels","volume":"13","author":"G Chowell","year":"2019","journal-title":"PLoS Negl Trop Dis."},{"issue":"8","key":"ppat.1010078.ref007","doi-asserted-by":"crossref","first-page":"e0004802","DOI":"10.1371\/journal.pntd.0004802","article-title":"Next Steps for Ebola Vaccination: Deployment in Non-Epidemic, High-Risk Settings","volume":"10","author":"LA Skrip","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"ppat.1010078.ref008","unstructured":"Ebola Vaccine Team B, Wellcome Trust, CIDRAP. Completing the Development of Ebola Vaccines: Current Status, Remaining Challenges, and Recommendations. January 2017 [cited 2021 Aug 1]. Available from: https:\/\/www.cidrap.umn.edu\/sites\/default\/files\/public\/downloads\/ebola_team_b_report_3-011717-final_0.pdf."},{"issue":"3","key":"ppat.1010078.ref009","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.cell.2015.12.022","article-title":"Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection","volume":"164","author":"AI Flyak","year":"2016","journal-title":"Cell"},{"issue":"7","key":"ppat.1010078.ref010","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"SM Jones","year":"2005","journal-title":"Nat Med"},{"issue":"7","key":"ppat.1010078.ref011","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1473-3099(18)30165-8","article-title":"Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study","volume":"18","author":"A Huttner","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"ppat.1010078.ref012","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/jama.2015.1995","article-title":"Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick","volume":"313","author":"L Lai","year":"2015","journal-title":"JAMA"},{"issue":"Suppl 3","key":"ppat.1010078.ref013","doi-asserted-by":"crossref","first-page":"S1075","DOI":"10.1093\/infdis\/jir349","article-title":"Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections","volume":"204","author":"TW Geisbert","year":"2011","journal-title":"J Infect Dis"},{"issue":"2","key":"ppat.1010078.ref014","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3201\/eid2102.141649","article-title":"Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses","volume":"21","author":"A Marzi","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"ppat.1010078.ref015","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Mvabea Assessment report: EMA\/323668\/2020 (procedure No. EMEA\/H\/C\/005343\/0000). 28 May 2020 [cited 2021 Aug 1]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/mvabea-epar-public-assessment-report_en.pdf."},{"issue":"22","key":"ppat.1010078.ref016","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1016\/j.vaccine.2020.09.018","article-title":"Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk\/benefit assessment","volume":"39","author":"J Custers","year":"2021","journal-title":"Vaccine"},{"issue":"15","key":"ppat.1010078.ref017","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial","volume":"315","author":"ID Milligan","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"ppat.1010078.ref018","doi-asserted-by":"crossref","first-page":"e0192312","DOI":"10.1371\/journal.pone.0192312","article-title":"A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates","volume":"13","author":"B Callendret","year":"2018","journal-title":"PLoS ONE"},{"key":"ppat.1010078.ref019","unstructured":"World Health Organization. Ebola virus disease- Democratic Republic of Congo External Situation Report 98. 23 Jun 20 [cited 2021 Oct 18]. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/332654\/SITREP_EVD_DRC_20200623-eng.pdf."},{"issue":"17","key":"ppat.1010078.ref020","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA","volume":"374","author":"K Ewer","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"ppat.1010078.ref021","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","article-title":"Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial","volume":"16","author":"MD Tapia","year":"2016","journal-title":"Lancet Infect Dis."},{"issue":"8","key":"ppat.1010078.ref022","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/infdis\/jiy639","article-title":"Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal","volume":"219","author":"N Venkatraman","year":"2019","journal-title":"J Infect Dis"},{"issue":"1","key":"ppat.1010078.ref023","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","article-title":"Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial","volume":"16","author":"MD Tapia","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"ppat.1010078.ref024","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/21645515.2016.1238535","article-title":"Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I\/II trial in healthy adults in Russia","volume":"13","author":"IV Dolzhikova","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"10069","key":"ppat.1010078.ref025","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(16)32617-4","article-title":"Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"389","author":"FC Zhu","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"ppat.1010078.ref026","doi-asserted-by":"crossref","first-page":"e01190","DOI":"10.1128\/JVI.01190-17","article-title":"Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge","volume":"92","author":"D Matassov","year":"2018","journal-title":"J Virol"},{"issue":"4","key":"ppat.1010078.ref027","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1473-3099(19)30614-0","article-title":"Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.","volume":"20","author":"DK Clarke","year":"2020","journal-title":"Lancet Infect Dis."},{"issue":"11","key":"ppat.1010078.ref028","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1128\/CVI.00162-06","article-title":"A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial","volume":"13","author":"JE Martin","year":"2006","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"ppat.1010078.ref029","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/infdis\/jiu511","article-title":"Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial","volume":"211","author":"UN Sarwar","year":"2015","journal-title":"J Infect Dis"},{"issue":"9977","key":"ppat.1010078.ref030","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(14)62385-0","article-title":"Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial","volume":"385","author":"H Kibuuka","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"ppat.1010078.ref031","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/infdis\/jiz518","article-title":"Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy Adults","volume":"222","author":"L Fries","year":"2020","journal-title":"J Infect Dis"},{"key":"ppat.1010078.ref032","unstructured":"World Health Organization. UNICEF, WHO, IFRC and MSF announce the establishment of a global Ebola vaccine stockpile. 2021 Jan 12 [cited 2021 Oct 4]. Available at: https:\/\/www.who.int\/news\/item\/12-01-2021-unicef-who-ifrc-and-msf-announce-the-establishment-of-a-global-ebola-vaccine-stockpile."}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1010078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T13:32:16Z","timestamp":1639056736000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1010078"}},"subtitle":[],"editor":[{"given":"Rebecca Ellis","family":"Dutch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,12,9]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1010078","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,9]]}}}